Strontium-89 chloride for pain palliation in prostatic skeletal malignancy.

In a multi-centre study strontium-89 was shown to be effective in relieving bone pain from prostatic carcinoma in patients who had failed conventional therapies. Of 83 patients assessed at 3 months, following the administration of a dose of at least 1.5 MBq/kg, 75% derived benefit and 22% became pain free. Symptomatic improvement usually occurred within 6 weeks and continued for between 4 and 15 months (mean 6 months). Based on the dose estimation part of this study the recommended dose of strontium-89 is 150 MBq. Toxicity was low, provided platelet levels were above 100 x 10(9) l-1 at the time of treatment. Repeat treatments with strontium-89 may be given at intervals of not less than 3 months. Strontium-89 is administered intravenously on an out-patient basis with no special radiological protection precautions.

[1]  A. Kagan,et al.  Evaluation of radiation therapy for bone metastases: pain relief and quality of life , 1977 .

[2]  C. Rowland.  Single fraction half body radiation therapy. , 1979, Clinical radiology.

[3]  Debruyne Fm,et al.  LHRH-analogues therapy for metastatic prostate cancer. , 1988 .

[4]  W. S. Maxfield,et al.  The Use of Radioactive Phosphorus and Testosterone in Metastatic Bone Lesions from Breast and Prostate , 1958, Southern medical journal.

[5]  J. Storaasli,et al.  Palliation of Osseous Metastases from Breast Carcinoma with Radioactive Phosphorus Alone and in Combination with Adrenalectomy , 1961 .

[6]  P. Walsh,et al.  Hormonal Therapy of Prostatic Cancer , 1980, Cancer.

[7]  D. Tong,et al.  The palliation of symptomatic osseous metastases final results of the study by the radiation therapy oncology group , 1982, Cancer.

[8]  S. Jacobs.  Spread of prostatic cancer to bone. , 1983, Urology.

[9]  J. Yarnold,et al.  Prospective randomised trial of single and multifraction radiotherapy schedules in the treatment of painful bony metastases. , 1986, Radiotherapy and oncology : journal of the European Society for Therapeutic Radiology and Oncology.

[10]  A. Glicksman,et al.  Single-dose radiation therapy in the palliation of metastatic disease. , 1969, Radiology.

[11]  M. Winston.  Radioisotope therapy in bone and joint disease. , 1979, Seminars in nuclear medicine.

[12]  N. Burnet,et al.  Phosphorus-32 for intractable bony pain from carcinoma of the prostate. , 1990, Clinical oncology (Royal College of Radiologists (Great Britain)).

[13]  K. Roesdahl,et al.  Single-dose irradiation of bone metastases. , 1976, Acta radiologica: therapy, physics, biology.

[14]  A. McEwan,et al.  Strontium-89 therapy: measurement of absorbed dose to skeletal metastases. , 1988, Journal of nuclear medicine : official publication, Society of Nuclear Medicine.

[15]  G. Hibbs,et al.  Effective bone palliation as related to various treatment regimens , 1976, Cancer.

[16]  J. A. Spicer,et al.  Treatment of metastatic bone pain with strontium-89. , 1987, International journal of radiation applications and instrumentation. Part B, Nuclear medicine and biology.

[17]  A. McEwan,et al.  Sr-89 therapy: Strontium kinetics in disseminated carcinoma of the prostate , 1986, European Journal of Nuclear Medicine.

[18]  M. Glaser,et al.  Carcinoma of the prostate: the treatment of bone metastases by radiophosphorus. , 1981, Clinical radiology.

[19]  P. Rubin,et al.  Single-dose half-body irradiation for the palliation of multiple bone metastases from solid tumors: a preliminary report. , 1981, International journal of radiation oncology, biology, physics.